Evidence map›Paper›PMID 30464040›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2019

Phase I Study of CTT1057, an

Spencer C Behr, Rahul Aggarwal, Henry F VanBrocklin, Robert R Flavell, Kenneth Gao, Eric J Small, Joseph Blecha, Salma Jivan, Thomas A Hope, Jeffry P Simko and 11 more

Open access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 47 citations in OpenAlex.

  1. Imaging Efficacy of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Trial
  2. Safety, Dosimetry, and Feasibility of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Trial
  3. A microdose clinical trial to evaluate [European journal of nuclear medicine and molecular imaging · 2021
    Trial
  4. Article
  5. Review
  6. Modular Smart Molecules for PSMA-Targeted Chemotherapy.Molecular cancer therapeutics · 2022
    Article
  7. Review
  8. Advances in PSMA theranostics.Translational oncology · 2022
    Article
  9. Synthesis, preclinical evaluation, and first-in-human study of AlEuropean journal of nuclear medicine and molecular imaging · 2022
    Article
  10. Review
  11. Review
  12. Review
  13. Humanization, Radiolabeling and Biodistribution Studies of an IgGPharmaceuticals (Basel, Switzerland) · 2021
    Article
  14. Article
  15. The aluminium-[EJNMMI radiopharmacy and chemistry · 2021
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Spencer C BehrDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California spencer.behr@ucsf.edu.
Rahul AggarwalDepartment of Medicine, University of California, San Francisco, San Francisco, California.
Henry F VanBrocklinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Kenneth GaoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Eric J SmallDepartment of Medicine, University of California, San Francisco, San Francisco, California.
Joseph BlechaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Salma JivanDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Jeffry P SimkoDepartment of Pathology, University of California, San Francisco, San Francisco, California; and.
John KurhanewiczDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Susan M NoworolskiDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Natalie J KornDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Romelyn De Los SantosDepartment of Pathology, University of California, San Francisco, San Francisco, California; and.
Matthew R CooperbergDepartment of Urology, University of California, San Francisco, San Francisco, California.
Peter R CarrollDepartment of Urology, University of California, San Francisco, San Francisco, California.
Hao G NguyenDepartment of Urology, University of California, San Francisco, San Francisco, California.
Kirsten L GreeneDepartment of Urology, University of California, San Francisco, San Francisco, California.
Beatrice Langton-WebsterCancer Targeted Technology, Woodinville, Washington.
Clifford E BerkmanCancer Targeted Technology, Woodinville, Washington.
Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
University of California, San Francisco · USCancer Targeted Technology (United States) · US

Funding

Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate CancerR44CA239461 · NCI · CANCER TARGETED TECHNOLOGY, LLC · PI LANGTON-WEBSTER, BEATRICE · 2019 to 2021
$3.2M
Clinical Evaluation of a Novel Prostate Cancer PET DiagnosticR44CA192451 · NCI · CANCER TARGETED TECHNOLOGY, LLC · PI LANGTON-WEBSTER, BEATRICE · 2015 to 2016
$2.0M
Development of a novel PET imaging agent for prostate cancerR44CA153481 · NCI · CANCER TARGETED TECHNOLOGY, LLC · PI LANGTON-WEBSTER, BEATRICE · 2010 to 2011
$1.5M
Development of a PSMA-Targeted Small-Molecule Drug Conjugate for Prostate CancerR43CA221511 · NCI · CANCER TARGETED TECHNOLOGY, LLC · PI LANGTON-WEBSTER, BEATRICE · 2018 to 2018
$300k
NCI NIH HHS R43 CA221511NCI NIH HHS R44 CA153481NCI NIH HHS R44 CA192451NCI NIH HHS R44 CA239461
6 · The paper itself

Abstract

Agents targeting prostate-specific membrane antigen (PSMA) comprise a rapidly emerging class of radiopharmaceuticals for diagnostic imaging of prostate cancer. Unlike most other PSMA agents with a urea backbone, CTT1057 is based on a phosphoramidate scaffold that irreversibly binds to PSMA. We conducted a first-in-humans phase I study of CTT1057 in patients with localized and metastatic prostate cancer.

Indexed as

Fluorine RadioisotopesAgedAmidesAntigens, SurfaceCohort StudiesGlutamate Carboxypeptidase IIHumansIsotope LabelingMaleMiddle AgedPhosphoric AcidsPositron-Emission TomographyProspective StudiesProstatic NeoplasmsSafetyTissue DistributionAmidesAntigens, SurfaceFluorine-18Fluorine RadioisotopesFOLH1 protein, humanGlutamate Carboxypeptidase IIphosphoramidic acidPhosphoric AcidsCTT1057dosimetryPETprostate cancerPSMA

Identifiers

PMID30464040
PMCPMC6604687
OpenAlexW2901253757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.